Financials data is unavailable for this security.
Cash flow in SEKView more
In 2023, cash reserves at Oncopeptides AB fell by 171.11m. Cash Flow from Financing totalled 106.89m or 303.49% of revenues. In addition the company used 279.49m for operations while cash used for investing totalled 116.00k.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.9134 |
---|---|
Tangible book value per share | 0.9134 |
More ▼
Balance sheet in SEKView more
Current ratio | 3.48 |
---|---|
Quick ratio | 3.44 |
Total debt/total equity | 0.7203 |
---|---|
Total debt/total capital | 0.4187 |
More ▼